Affirmed Therapeutics BV (AFMD) Shares Down 4.3%
Shares of Affirmed Therapeutics BV (NASDAQ:AFMD) dropped 4.3% during mid-day trading on Wednesday . The company traded as low as $2.45 and last traded at $2.47, with a volume of 70,182 shares trading hands. The stock had previously closed at $2.58.
AFMD has been the topic of a number of research reports. Wells Fargo & Co. reiterated a “buy” rating on shares of Affirmed Therapeutics BV in a report on Wednesday, May 18th. Jefferies Group reduced their target price on shares of Affirmed Therapeutics BV from $5.00 to $4.00 and set a “hold” rating on the stock in a report on Thursday, May 19th. Finally, Leerink Swann downgraded shares of Affirmed Therapeutics BV from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $8.00 to $3.00 in a report on Friday, August 12th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $8.63.
The stock’s market capitalization is $83.72 million. The company has a 50-day moving average price of $2.79 and a 200-day moving average price of $3.39.
Affirmed Therapeutics BV (NASDAQ:AFMD) last announced its quarterly earnings results on Wednesday, August 10th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.22) by $0.05. The company had revenue of $2.07 million for the quarter, compared to analysts’ expectations of $2.10 million. The business’s quarterly revenue was down 6.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.19) earnings per share. Equities analysts predict that Affirmed Therapeutics BV will post ($1.12) earnings per share for the current year.
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.